Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.22.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Cumulative Effect, Period of Adoption, Adjustment
Legacy Convertible Preferred Stock
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjusted Balance
Common Stock
Cumulative Effect, Period of Adoption, Adjusted Balance
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjusted Balance
Accumulated Other Comprehensive (Loss) Income
Cumulative Effect, Period of Adoption, Adjusted Balance
Legacy Convertible Preferred Stock
Common Stock
In-process research and development
Common Stock
Restricted Stock awards
Common Stock
Restricted Stock Units
Common Stock
Additional Paid-In Capital
In-process research and development
Additional Paid-In Capital
Restricted Stock awards
Additional Paid-In Capital
Restricted Stock Units
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
In-process research and development
Restricted Stock awards
Restricted Stock Units
Total
BALANCE at Dec. 31, 2019 $ (436,553)                 $ 436,553                            
BALANCE (in shares) at Dec. 31, 2019 (100,038,109)                 100,038,109                            
BALANCE at Dec. 31, 2019   $ 13 $ 436,520 $ 436,533 $ 16 $ 453,242 $ (294,262) $ 75 $ 159,071         $ 3       $ 16,722 $ (294,262) $ 75       $ (277,462)
BALANCE (in shares) at Dec. 31, 2019   128,100,821     154,913,934                 26,813,113                    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                
Exercise of Common Stock options                                   325           325
Exercise of Common Stock options (in shares)                           521,925                    
Vesting of restricted Common Stock                           $ 1       6           7
Vesting of restricted Common Stock (in shares)                           5,307,357                    
Repurchase of shares for employee tax withholdings                                   (101)           (101)
Repurchase of shares for employee tax withholdings (in shares)                           (9,308)                    
Issuance of Common Stock for acquisitions                                   500           500
Issuance of Common Stock for acquisitions (in shares)                           61,060                    
Stock-based compensation expense                                   8,006           8,006
Common Stock warrants issued and exercised                                   1,915           1,915
Common Stock warrants issued and exercised (in shares)                           692,366                    
Reverse recapitalization, net of transaction costs                           $ 6       380,295           380,301
Reverse recapitalization, net of transaction costs (in shares)                           63,139,263                    
Net loss                                     (34,015)         (34,015)
Other comprehensive income (loss)                                       (84)       (84)
BALANCE at Dec. 31, 2020                           $ 23       844,188 (328,277) (9)       $ 515,925
BALANCE (in shares) at Dec. 31, 2020                           224,626,597                    
BALANCE (in shares) at Dec. 31, 2021                                               100,038,109
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                                
Exercise of Common Stock options                           $ 1       6,425           $ 6,426
Exercise of Common Stock options (in shares)                           5,732,247                    
Vesting of restricted Common Stock (in shares)                           491,293                    
Repurchase of shares for employee tax withholdings                               $ (958) $ (541)         $ (958) $ (541)  
Repurchase of shares for employee tax withholdings (in shares)                       (109,150) (61,498)                      
Issuance of Common Stock for acquisitions                           $ 5       620,585           620,590
Issuance of Common Stock for acquisitions (in shares)                           57,267,401                    
Stock-based compensation expense                                   28,778           28,778
Vesting of restricted stock units (in shares)                           650,777                    
Issuance of common stock for acquired in-process research and development                             $ 4,300           $ 4,300     4,300
Issuance of common stock for acquired in-process research and development (in shares)                     334,370                          
Vesting of Trine Founder shares (in shares)                           1,850,938                    
Common Stock issued in connection with warrants exercised                           $ 2       320,567           320,569
Common Stock issued in connection with warrants exercised (in shares)                           20,690,975                    
Net loss                                     (240,334)         (240,334)
Other comprehensive income (loss)                                       (6,405)       (6,405)
BALANCE at Dec. 31, 2021                           $ 31       $ 1,823,344 $ (568,611) $ (6,414)       $ 1,248,350
BALANCE (in shares) at Dec. 31, 2021                           311,473,950